找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biomarkers in Cancer; Victor R. Preedy,Vinood B. Patel Living reference work 20200th edition

[復(fù)制鏈接]
樓主: Annihilate
61#
發(fā)表于 2025-4-1 04:35:42 | 只看該作者
Breast Cancer: Serum TPS as a Biomarker,nformation and establishing patient responses to therapy. A main limitation of TPS is that it is not “organ specific,” which impedes diagnostic utility. Additionally, TPS levels are altered according to inflammation conditions, such as liver cirrhosis, ovulation, and menopausal status. Further clini
62#
發(fā)表于 2025-4-1 08:58:46 | 只看該作者
CA 19-9 as a Serum Biomarker in Cancer, used most commonly as a biomarker in pancreatic cancer as a prognostic and predictive tool and less commonly in other malignancies. This chapter will focus mainly on utility of CA 19-9 in pancreatic cancer and biliary tract cancers.
63#
發(fā)表于 2025-4-1 11:27:55 | 只看該作者
Cancer Cardiotoxicity and Cardiac Biomarkers,ike targeted therapy (i.e., trastuzumab) or angiogenesis inhibitors are all associated with some form of cardiac toxicity: while targeted drugs may induce a reversible damage, angiogenesis inhibitors have a prothrombotic activity, which leads to a high incidence of thromboembolic events..Patients we
64#
發(fā)表于 2025-4-1 17:19:43 | 只看該作者
Carcinoembryonic Antigen-Family Cell Adhesion Molecules (CEACAM) as Colorectal Cancer Biomarkers,tigen (CEA) is the biomarker most frequently used in colorectal cancer. It is effective in the surveillance of colorectal cancer patients and in monitoring the efficacy of therapy, whereas it is less useful in colorectal screening. Recent studies indicate that also CEA-related proteins (CEACAMs) are
65#
發(fā)表于 2025-4-1 19:35:51 | 只看該作者
Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytand Ki-67 (MIB-1) overexpression and UroVysion (multicolor fluorescence in situ hybridization kit for detecting copy number aberrations in chromosomes 3, 7, and 17, and the 9p21 locus), are promising for predicting disease progression and tumor recurrence in NMIBC. Further validation with a prospect
66#
發(fā)表于 2025-4-2 01:56:39 | 只看該作者
Circulating Biomarkers in Hodgkin Lymphoma,Although PET/CT is currently the most important tool used, interpretation is imperfect with low false-negative rates countered by high false positives. Furthermore, PET/CT is unavailable in many rural or underprivileged centers and, even in the most advantaged centers, is impractical for frequent te
67#
發(fā)表于 2025-4-2 03:51:29 | 只看該作者
Circulating Tumor Cells as Biomarkers in Cancer,aggressive adjuvant therapy. Furthermore, various studies have shown that temporal monitoring of CTCs can be used to evaluate patient responses to therapy and to detect genetic and phenotypic changes to tumors in real time, allowing more effective treatment guidance.
68#
發(fā)表于 2025-4-2 07:19:50 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-18 16:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
石渠县| 兰西县| 衡山县| 襄垣县| 万载县| 黄骅市| 庆城县| 高邮市| 临清市| 漳州市| 屏东县| 西宁市| 长丰县| 碌曲县| 德昌县| 嘉鱼县| 海兴县| 锡林浩特市| 红桥区| 孝昌县| 安图县| 离岛区| 兴安盟| 历史| 滨州市| 南丹县| 白山市| 宁海县| 雅江县| 舞阳县| 松滋市| 永城市| 贵州省| 洛隆县| 汝城县| 西乡县| 云和县| 汤阴县| 文昌市| 南溪县| 和政县|